Paul Stanton
Gastroenterology · Tulsa, OKNPI 1407841794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 30.0% of the total. Reporting peaked in 2023 at $2,415 and has fallen 98.3% since, to $41 in 2024.
Across 365 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$680
- Johnson & Johnson$327
- Ferring Pharmaceuticals Inc.$287
- Bristol Myers Squibb$246
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,314100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $1,903 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 75 | $1,308 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $680 |
| Johnson & Johnson | 22 | $327 |
| Ferring Pharmaceuticals Inc. | 17 | $287 |
| Bristol Myers Squibb | 14 | $246 |
| Gilead | 9 | $174 |
| Olympus America Inc. | 9 | $173 |
| Daiichi Sankyo Inc. | 8 | $163 |
| Regeneron Healthcare Solutions, Inc. | 9 | $149 |
| Ardelyx, Inc. | 5 | $89 |
| Pfizer | 6 | $88 |
| QOL Medical, LLC | 5 | $78 |
| Sanofi | 4 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $68 |
| Merck | 4 | $65 |
| Medtronic | 1 | $59 |
| Braintree Laboratories, Inc. | 3 | $52 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| Amgen | 3 | $40 |
| Mylan Institutional Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Organon | 3 | $32 |
| UCB, Inc. | 2 | $31 |
| Intercept Pharmaceuticals, Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $16 |
How this compares
$6,332 in reported general payments places this provider in the 55th percentile of 133 gastroenterology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 15 | $2,072 |
| Famotidine | 34 | $779 |
| Lansoprazole | 11 | $760 |
| Pantoprazole Sodium | 25 | $323 |
| Dicyclomine Hcl | 11 | $317 |
| Omeprazole | 24 | $234 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Tulsa
- Jeffrey HuntTulsa$155K
- Harvey TatumTulsa$27K
- Roy ThompsonTulsa$16K
- Aaron FiekerTulsa$15K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- David MorrisTulsa$13K
- Patrick VolakTulsa$13K
- Matt BlankenshipTulsa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.